This therapeutic concept exploits the GPX4-independent ferroptosis suppression pathway mediated by FSP1 (Ferroptosis Suppressor Protein 1, formerly AIFM2) and Coenzyme Q10 (CoQ10). By enhancing the FSP1-CoQ10 redox system, this approach aims to prevent iron-dependent lipid peroxidation in neurons — a key pathological process in Alzheimer's disease, Parkinson's disease, and amyotrophic lateral sclerosis.
Ferroptosis is an iron-dependent, non-apoptotic cell death mechanism characterized by:
- Accumulation of lipid peroxides
- Depletion of glutathione
- Inhibition of GPX4 (glutathione peroxidase 4)
- Iron-mediated Fenton reactions
Evidence for ferroptosis involvement in neurodegenerative diseases:
-
Alzheimer's disease: Elevated iron in amyloid plaques; lipid peroxidation markers (4-HNE, MDA) in brain tissue; GPX4 downregulation in AD brains.
-
Parkinson's disease: Iron accumulation in substantia nigra; neuromelanin-bound iron release during degeneration; ferroptosis-like morphology in PD models.
-
ALS: Lipid peroxidation in motor neurons; reduced GPX4 in SOD1 models; ferroptosis inhibitors rescue motor neuron death.
FSP1 suppresses ferroptosis through a GPX4-independent mechanism:
- NADH-dependent CoQ reduction: FSP1 catalyzes NADH → CoQ10 conversion, generating ubiquinol (CoQ10H2)
- Membrane antioxidant: CoQ10H2 scavenges lipid peroxyl radicals in membranes
- Independent of glutathione: Works even when GPX4/GSH system is compromised
This makes FSP1-CoQ10 activation particularly valuable in:
- Advanced disease stages where GSH is depleted
- Combination with GPX4 inhibitors (system redundancy)
- Situations where ferroptosis is the primary death mechanism
Small-molecule FSP1 activators:
- Diabetic drugs with FSP1 activity: Pioglitazone, rosiglitazone (PPARγ agonists with off-target FSP1 activation)
- NAD+ precursors: NAD+ boosters (nicotinamide riboside, nicotinamide mononucleotide) enhance FSP1 activity (NADH-dependent)
- Novel FSP1-specific activators: Under development by several pharmaceutical companies
Delivery: Oral (PPARγ agonists); intranasal or oral (NAD+ precursors)
High-dose CoQ10:
- Ubiquinol (reduced form) preferred over ubiquinone
- Nanoemulsion formulations for enhanced CNS penetration
- Dose: 300-600 mg/day (typical for mitochondrial disorders)
CoQ10 analogs:
- Idebenone: Synthetic analog with enhanced antioxidant potency
- MitoQ: Mitochondria-targeted CoQ10 (TPP conjugation)
- MitoVitE: Mitochondria-targeted vitamin E (alternative mechanism)
Rationale: Dual approach — enhance antioxidant defense AND reduce iron availability
Implementation:
- Deferoxamine or deferasirox (iron chelation) — limited CNS penetration
- Intrajejunal deferoxamine — better CNS access
- Novel CNS-penetrant chelators: VK28, M30
- Combined with FSP1 activators
| Dimension |
Score |
Rationale |
| Novelty |
7 |
FSP1 pathway relatively new (discovered 2019); CoQ10 repurposing but novel combination |
| Mechanistic Rationale |
9 |
Strong mechanistic link between ferroptosis and neurodegeneration; FSP1 pathway well-characterized |
| Root-Cause Coverage |
8 |
Addresses iron-dependent lipid peroxidation — upstream of many death pathways |
| Delivery Feasibility |
8 |
Multiple approved compounds (CoQ10, idebenone, iron chelators); good BBB penetration with formulations |
| Safety Plausibility |
8 |
Well-established safety profiles for CoQ10, NAD+ precursors, iron chelators |
| Combinability |
9 |
Highly synergistic with GPX4 activators, ferroptosis inducers (in cancer), and antioxidant cocktails |
| Biomarker Availability |
8 |
Lipid peroxidation markers (4-HNE, MDA, F2-isoprostanes); serum/CSF iron; FSP1 expression |
| De-risking Path |
8 |
Clear biomarkers; established clinical use of components; clear mechanistic readouts |
| Multi-disease Potential |
8 |
AD, PD, ALS, FTD, Huntington's all show ferroptosis involvement |
| Patient Impact |
8 |
Addresses fundamental oxidative damage — fundamental disease modification |
Total: 81/100
- Elevated lipid peroxidation markers (4-HNE in CSF, plasma F2-isoprostanes)
- Reduced GPX4 activity or expression
- Iron accumulation on MRI (particularly in PD substantia nigra)
- Disease stage: early-to-mid disease (more residual neurons to protect)
- Lipid peroxidation: 4-HNE, MDA, F2-isoprostanes in CSF/ plasma
- Iron status: Serum ferritin, transferrin saturation; MRI R2* in basal ganglia
- CoQ10 levels: Plasma CoQ10/CoQ10H2 ratio
- FSP1 activity: NADH:CoQ10 reductase activity in lymphocytes
- Clinical endpoints: Cognitive/functional decline; motor scores in PD
- In vitro: Ferroptosis induction in patient-derived neurons (iPSC); rescue with FSP1 agonists
- Ex vivo: Brain slice cultures; lipid peroxidation assays
- In vivo: Ferroptosis models (GPX4 knockout, erastin treatment); behavioral rescue
- Phase I/II: CoQ10/idebenone + NAD+ precursor in AD/PD; biomarker optimization
- Phase IIa: Biomarker-selected patients (high lipid peroxidation); mechanistic readouts
- Phase IIb: Disease modification endpoints
- Phase III: Registration trial
- Start with safest component (CoQ10) before adding more potent but riskier agents
- Monitor for iron chelation-related anemia
- Avoid in conditions where ferroptosis is needed (cancer surveillance)
- FSP1-CoQ10 pathway + GPX4-GSH pathway = redundancy
- Implementation: CoQ10 + selenium (GPX4 cofactor) + NAC (GSH precursor)
- Particularly valuable in advanced disease where one pathway may fail
- CoQ10 in membranes + vitamin E in lipid rafts = comprehensive lipid protection
- Implementation: CoQ10 + alpha-tocopherol (avoid high-dose alone due to pro-oxidant effect)
- Reduce iron availability + enhance antioxidant defense
- Implementation: CoQ10 + deferoxamine or novel CNS chelator
- NAD+ required for FSP1 activity
- Combined with SIRT1 activators (also NAD+-dependent)
- Implementation: CoQ10 + NMN/NR + resveratrol/SRT2104
- FSP1 agonist screening: Screen small molecule libraries for FSP1 activators using NADH:CoQ reductase assay. Prioritize compounds with EC50 < 100 nM and >5-fold selectivity over related enzymes.
- CoQ10 formulation optimization: Develop brain-penetrant CoQ10 formulations (nanoemulsion, cyclodextrin complexes) achieving >10x brain:plasma ratio in mice.
- Lipid peroxidation assay: Validate suppression of lipid ROS using BODIPY-C11 in patient-derived neurons. Confirm >50% reduction at therapeutic doses.
- GPX4 independence confirmation: Demonstrate FSP1-CoQ10 works in GPX4-knockout cells to validate GPX4-independent mechanism.
- Patient enrichment: Select patients with elevated CSF/serum lipid peroxidation markers (F2-isoprostanes, 4-HNE). Consider Ferroptosis Susceptibility Index based on iron, GSH, and lipid profiles.
- Dose-finding design: Sequential dose escalation starting at 100mg CoQ10 equivalents. Primary endpoint: plasma F2-isoprostane reduction at 3 months.
- Biomarker stratification: Use lipid peroxidation signatures to guide dosing and identify responders. Implement adaptive design with biomarker-guided enrichment.
- CoQ10 formulation companies: Partner with companies specializing in brain-penetrant CoQ10 (Kaneka, Mitsubishi Gas Materials) for formulation development.
- Ferroptosis pipeline: Coordinate with companies developing GPX4 inhibitors for cancer (e.g., discussion with oncology groups at GSK, Novartis) to share safety data on ferroptosis modulation.
- Diagnostic companions: Partner with companies offering oxidative stress biomarker panels (e.g., Cleveland BioLabs, Astellas) for patient selection and endpoint validation.
| Phase |
Duration |
Key Milestones |
| Lead Discovery |
12-18 months |
FSP1 agonist screen, CoQ10 formulation optimization |
| Preclinical (IND-enabling) |
18-24 months |
GLP toxicology, efficacy in ferroptosis models |
| IND-enabling Studies |
12-18 months |
Complete GLP toxicology, CMC, pre-IND meeting |
| Phase I |
12-18 months |
Safety, dose-ranging in neurodegeneration patients |
- Lead discovery: $3-6M
- Preclinical development: $10-18M
- IND-enabling studies: $8-14M
- Phase I trials: $12-20M
- Total to Phase I: $33-58M
- MIT — Dr. Brent Stockell (ferroptosis biology)
- Columbia — Dr. Brent R. Stockell (lipid peroxidation)
- UCLA — Dr. Varghese John (AD clinical trials)
- University of Michigan — Dr. Michael J. Fox (PD biomarkers)
- Kaneka — Brain-penetrant CoQ10 formulations
- MediBIR — Ferroptosis pipeline
- Generic CoQ10 manufacturers — Formulation partnerships
| Risk |
Likelihood |
Impact |
Mitigation |
| FSP1 agonist potency |
Medium |
High |
Screen large compound libraries |
| CoQ10 brain penetration |
Medium |
High |
Nanoparticle formulations |
| Lipid peroxidation rebound |
Low |
Medium |
Monitor in long-term studies |
| Dimension |
Score |
Rationale |
| Novelty |
7/10/10 |
FSP1 as therapeutic target is novel; ferroptosis inhibition emerging |
| Mechanistic Rationale |
8/10/10 |
FSP1 catalyzes CoQ10 reduction; blocks lipid peroxidation and ferroptosis |
| Addresses Root Cause |
7/10/10 |
Addresses ferroptosis - iron-dependent cell death pathway in neurodegeneration |
| Delivery Feasibility |
6/10/10 |
CoQ10 supplementation established; FSP1 activators in development |
| Safety Plausibility |
7/10/10 |
CoQ10 has excellent safety profile; FSP1-specific compounds being optimized |
| Combinability |
7/10/10 |
Synergizes with other ferroptosis inhibitors and antioxidant approaches |
| Biomarker Availability |
6/10/10 |
Lipid peroxidation markers available; ferroptosis biomarkers emerging |
| De-risking Path |
6/10/10 |
CoQ10 trials in neurodegeneration ongoing; FSP1-specific drugs early stage |
| Multi-disease Potential |
8/10/10 |
Highly relevant for AD, PD, ALS, Huntington disease, stroke |
| Patient Impact |
7/10/10 |
Could prevent neuronal death in acute and chronic neurodegeneration |
| Total |
69/100 |
|